Talk Title: “PARP-1 Radiotracers for PET Imaging and Small Molecule Targeted Alpha Radiotherapeutics” PARP inhibitors (PARPi) have proven to be an important class of compounds for treating cancer patients having BRCA1/2 mutations or other deficiencies in homologous recombination repair. Unfortunately, ~50% of patients having BRCA1/2 mutations do not respond to PARPi, indicating that better biomarkers are needed to identify which patients are likely to benefit from this type of treatment…
Seminar Speaker- Dr. Robert Mach | April 23 | 11:00am CDT
